Wedbush Downgrades Zentalis Pharmaceuticals (ZNTL) to Neutral
Tweet
Share
E-mailGet Alerts ZNTL Hot Sheet
Price: $3.83 -0.26%
Rating Summary:
8 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Wedbush analyst Robert Driscoll downgraded Zentalis Pharmaceuticals (NASDAQ: ZNTL) from Outperform to Neutral with a price target of $12.00 (from $38.00).
For an analyst ratings summary and ratings history on Zentalis Pharmaceuticals click here. For more ratings news on Zentalis Pharmaceuticals click here.
Shares of Zentalis Pharmaceuticals closed at $10.20 yesterday.
You May Also Be Interested In
- Stella International Holdings (1836:HK) (SLNLF) PT Lowered to HK$10 at Macquarie
- Morgan Stanley Downgrades oOh!media (OML:AU) to Equalweight
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
